Connect with us

Hi, what are you looking for?

Smart Success StrategySmart Success Strategy

Investing

Republican senator claims RFK Jr. mRNA vaccine decision undermines Trump agenda

Sen. Bill Cassidy, R-La., has condemned the Department of Health and Human Services’ move to shift funding away from mRNA vaccine development, claiming it undermines President Donald Trump’s agenda to make the nation healthy again.

‘We reviewed the science, listened to the experts, and acted,’ Department of Health and Human Services Sec. Robert F. Kennedy Jr. said, according to an HHS press release.

‘BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.’

Cassidy registered his objection to the move.

‘It is unfortunate that the Secretary just canceled a half a billion worth of work, wasting the money which is already invested. He has also conceded to China an important technology needed to combat cancer and infectious disease. President Trump wants to Make America Healthy Again and Make America Great Again. This works against both of President Trump’s goals,’ the lawmaker said in a post on X. 

The HHS stated, ‘While some final-stage contracts (e.g., Arcturus and Amplitude) will be allowed to run their course to preserve prior taxpayer investment, no new mRNA-based projects will be initiated. HHS has also instructed its partner, Global Health Investment Corporation (GHIC), which manages BARDA Ventures, to cease all mRNA-based equity investments. In total, this affects 22 projects worth nearly $500 million. Other uses of mRNA technology within the department are not impacted by this announcement.’

Fox News Digital reached out to Cassidy’s office to request comment from the senator on Thursday, but did not receive a response by the time of publication.

Cassidy, who has served in the upper chamber since 2015, is aiming to get re-elected in 2026, though the incumbent faces competition from other Republicans who have also launched bids for the Senate seat.

In February 2021, Cassidy voted to convict Trump after the House impeachment in the wake of the January 6 episode at the U.S. Capitol. That Senate vote, which occurred after Trump had already left office, ultimately fell short of the threshold necessary to convict.

This post appeared first on FOX NEWS
Enter Your Information Below To Receive Latest News, And Articles.



    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Investing

    Ukrainian President Volodymyr Zelenskyy on Sunday thanked European leaders for backing his push to join this week’s U.S.–Russia summit, as Kyiv fears Washington and...

    Stock

    Kimberly-Clark said on Monday it will buy Tylenol maker Kenvue KVUE.N in a cash-and-stock deal valued at about $48.7 billion, to create one of...

    Stock

    President Donald Trump’s tariffs are hitting toy giants Mattel and Hasbro as the critical holiday season nears. Still, both companies see a successful year...

    Investing

    The FBI identified Keith Michael Lisa as the suspect wanted in connection to an attack this week on U.S. Attorney Alina Habba’s office. A...

    Disclaimer: smartsuccessstrategy.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smartsuccessstrategy.com